$INMB News

INmune Bio Announces Results From Exploratory Chi-Separation MRI Imaging Analyses From MINDFuL Phase 2 Clinical Trial Of XPro In Patients With Early Alzheimer's Disease

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

INmune Bio (INMB) Q1 2026 Earnings Transcript

INmune Bio, Inc. Q1 2026 Earnings Call Summary

INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript

INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum

INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update

INmune Bio Q1 EPS $(0.20) Beats $(0.22) Estimate.

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th

INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models

INmune Bio To Present New Preclinical Data For Anti-Tumor Growth Treatment INB03; Data To Be Presented At The American Association For Cancer Research Annual Meeting On April 17-22

INmune Bio To Present New Preclinical Data For Anti-Tumor Growth Treatment INB03; Data To Be Presented At The American Association For Cancer Research Annual Meeting On April 17-22

INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely

INmune Bio, Inc. Q4 2025 Earnings Call Summary

INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

INmune Bio Inc. Announces 2025 Results and Provides Business Update

INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript